Assessing immunogenicity of CRISPR-NCas9 engineered strain against porcine epidemic diarrhea virus

Fengsai Li,Haiyuan Zhao,Ling Sui,Fangjie Yin,Xinzi Liu,Guihai Guo,Jiaxuan Li,Yanping Jiang,Wen Cui,Zhifu Shan,Han Zhou,Li Wang,Xinyuan Qiao,Lijie Tang,Xiaona Wang,Yijing Li

DOI: https://doi.org/10.1007/s00253-023-12989-0

IF: 5

2024-03-03

Applied Microbiology and Biotechnology

Abstract:Porcine epidemic diarrhea (PED) caused by porcine epidemic diarrhea virus (PEDV), is an acute and highly infectious disease, resulting in substantial economic losses in the pig industry. Given that PEDV primarily infects the mucosal surfaces of the intestinal tract, it is crucial to improve the mucosal immunity to prevent viral invasion. Lactic acid bacteria (LAB) oral vaccines offer unique advantages and potential applications in combatting mucosal infectious diseases, making them an ideal approach for controlling PED outbreaks. However, traditional LAB oral vaccines use plasmids for exogenous protein expression and antibiotic genes as selection markers. Antibiotic genes can be diffused through transposition, transfer, or homologous recombination, resulting in the generation of drug-resistant strains. To overcome these issues, genome-editing technology has been developed to achieve gene expression in LAB genomes. In this study, we used the CRISPR-NCas9 system to integrate the PEDV S1 gene into the genome of alanine racemase-deficient Lactobacillus paracasei △ Alr HLJ-27 ( L. paracasei △ Alr HLJ-27 ) at the thymidylate synthase (thyA) site, generating a strain, S1/ △ Alr HLJ-27 . We conducted immunization assays in mice and piglets to evaluate the level of immune response and evaluated its protective effect against PEDV through challenge tests in piglets. Oral administration of the strain S1/ △ Alr HLJ-27 in mice and piglets elicited mucosal, humoral, and cellular immune responses. The strain also exhibited a certain level of resistance against PEDV infection in piglets. These results demonstrate the potential of S1/ △ Alr HLJ-27 as an oral vaccine candidate for PEDV control.

biotechnology & applied microbiology

What problem does this paper attempt to address?

The paper aims to address the issue of Porcine Epidemic Diarrhea (PED), an acute highly contagious disease caused by the Porcine Epidemic Diarrhea Virus (PEDV), which brings significant economic losses to the pig farming industry. Given that PEDV primarily infects the intestinal mucosal surface, enhancing mucosal immunity is crucial for preventing viral invasion. Lactic acid bacteria (LAB) oral vaccines have unique advantages and application potential in combating mucosal infectious diseases, making them an ideal method for controlling PED outbreaks.

However, traditional LAB oral vaccines use plasmid expression of exogenous proteins and antibiotic genes as selection markers. These antibiotic genes can spread through transposition, transfer, or homologous recombination, leading to the emergence of antibiotic-resistant strains. To overcome these issues, researchers have developed gene editing technologies to achieve gene expression in the LAB genome. In this study, researchers used the CRISPR-NCas9 system to integrate the S1 gene of PEDV into the thymidylate synthase (thyA) locus of alanine racemase-deficient Lactobacillus paracasei △Alr HLJ-27 (L. paracasei △Alr HLJ-27), generating a new strain S1/△Alr HLJ-27. The immune response level of this strain was evaluated through immunization trials in mice and piglets, and its protective effect against PEDV was assessed through piglet challenge trials.

The study showed that the S1/△Alr HLJ-27 strain could induce mucosal, humoral, and cellular immune responses through oral administration in mice and piglets, and exhibited some resistance to PEDV infection. These results suggest that the S1/△Alr HLJ-27 strain has potential application value as an oral vaccine candidate for controlling PEDV.